Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   41200   clinical trials with a EudraCT protocol, of which   6743   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-002579-83
    Sponsor's Protocol Code Number:54767414LUC2001
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2017-03-21
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2016-002579-83
    A.3Full title of the trial
    A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
    Étude de Phase 1b/2, randomisée, ouverte, évaluant le daratumumab administré en association à l’atézolizumab par rapport à l’atézolizumab seul chez des patients présentant un cancer bronchique non à petites cellules avancé ou métastatique déjà traité
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study of Daratumumab combined with Atezolizumab versus Atezolizumab in Previously Treated Subjects with Advanced Non-Small Cell Lung Cancer.
    Étude évaluant le daratumumab administré avec l’atézolizumab versus l’atézolizumab seul chez des patients présentant un cancer bronchique non à petites cellules avancé déjà traité
    A.3.2Name or abbreviated title of the trial where available
    CALLISTO
    A.4.1Sponsor's protocol code number54767414LUC2001
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorJanssen-Cilag International NV
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportJanssen Research & Development
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationPAREXEL International LLC
    B.5.2Functional name of contact point
    B.5.6E-mailclinicaltrial.enquiries@PAREXEL.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDaratumumab
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDARATUMUMAB
    D.3.9.1CAS number 945721-28-8
    D.3.9.2Current sponsor codeJNJ-54767414 (Daratumumab)
    D.3.9.3Other descriptive nameHUMAX-CD38
    D.3.9.4EV Substance CodeSUB175772
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typehuman monoclonal antibody
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name TECENTRIQ
    D.2.1.1.2Name of the Marketing Authorisation holderGenentech
    D.2.1.2Country which granted the Marketing AuthorisationUnited States
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAtezolizumab
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNATEZOLIZUMAB
    D.3.9.2Current sponsor codeRO5541267
    D.3.9.4EV Substance CodeSUB178312
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Carcinome bronchopulmonaire non à petites cellules (CBNPC) avancé ou métastatique
    E.1.1.1Medical condition in easily understood language
    A specific type of lung cancer called "Non-Small Cell Lung Cancer"
    Un type spécifique de cancer du poumon appelé "cancer bronchique non à petites cellules "
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.1
    E.1.2Level PT
    E.1.2Classification code 10029522
    E.1.2Term Non-small cell lung cancer stage IV
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.1
    E.1.2Level PT
    E.1.2Classification code 10029521
    E.1.2Term Non-small cell lung cancer stage IIIB
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To compare the overall response rate (ORR) in subjects treated with daratumumab in combination with atezolizumab versus atezolizumab alone.
    Comparer le taux de réponse globale (TRG) observé chez les patients traités par daratumumab en association à l’atézolizumab, par rapport à celui observé sous atézolizumab seul.
    E.2.2Secondary objectives of the trial
    - To assess the safety of the combination of daratumumab and atezolizumab
    - To compare the duration of response (DoR) in subjects treated with daratumumab in combination with atezolizumab versus atezolizumab alone
    - To compare the clinical benefit rate (CBR) in subjects treated with daratumumab in combination with atezolizumab versus atezolizumab alone
    - To compare progression-free survival (PFS) in subjects treated with daratumumab in combination with atezolizumab versus atezolizumab alone
    - To compare overall survival (OS) in subjects treated with daratumumab in combination with atezolizumab versus atezolizumab alone
    - To evaluate the pharmacokinetic and immunogenicity profile of daratumumab when given in combination with atezolizumab
    - To evaluate the pharmacokinetic and immunogenicity profile of atezolizumab when given in combination with daratumumab
    -Évaluer la tolérance de l’association du daratumumab et de l’atézolizumab
    -Comparer la durée de la réponse (DdR) observée chez les patients traités par daratumumab en association à l’atézolizumab, par rapport à celle observée sous atézolizumab seul
    -Comparer le taux de bénéfice clinique observé chez les patients traités par daratumumab en association à l’atézolizumab, par rapport à celui observé sous atézolizumab seul
    -Comparer la survie sans progression observée chez les patients traités par daratumumab en association à l’atézolizumab, par rapport à celui observé sous atézolizumab seul
    -Comparer la survie globale observée chez les patients traités par daratumumab en association à l’atézolizumab, par rapport à celui observé sous atézolizumab seul
    -Évaluer la pharmacocinétique et le profil d’immunogénicité du daratumumab administré en association à l’atézolizumab
    -Évaluer la pharmacocinétique et le profil d’immunogénicité de l’atézolizumab administré en association au daratumumab
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. ≥18 years of age
    2. ECOG performance status of 0 or 1.
    3. Have histologically or cytologically confirmed advanced or metastatic NSCLC (Stage IIIb or IV).
    4. Measurable disease, as defined by RECIST v1.1.
    5. Known PD-L1 tumor status as determined by an IHC assay performed by the central laboratory on tissue obtained at Screening.
    6. Specific laboratory results obtained within 14 days prior to first administration of study drug.
    7. A woman of childbearing potential must have a negative highly sensitive serum (b-human chorionic gonadotropin [b-hCG]) at Screening within 14 days prior to study drug administration.
    8. Contraceptive use by men or women should be consistent with local regulations regarding the use of contraceptive methods for subject participating in clinical studies.
    9. During the study and for a minimum of approximately 3 months after the last dose of daratumumab or 5 months after the last dose of atezolizumab, in addition to the highly effective method of contraception, a man
    - who is sexually active with a woman of childbearing potential must agree to use a barrier method of contraception (eg, condom with spermicidal foam/gel/film/cream/suppository)
    - who is sexually active with a woman who is pregnant must use a condom
    - must agree not to donate sperm.
    10. Willing and able to adhere to the prohibitions and restrictions specified in this protocol.
    11. Must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study.
    1. Adultes âgés d’au moins 18 ans.
    2. Indice de performances ECOG de 0 ou 1.
    3. Présence d’un CBNPC avancé ou métastatique confirmé histologiquement ou cytologiquement (Stade IIIb ou IV).
    4. Maladie mesurable, selon la définition des critères RECIST v1.1.
    5. Statut tumoral PD-L1 connu, d’après la détermination effectuée par le laboratoire central avec une analyse IHC sur un échantillon tissulaire prélevé à la sélection.
    6. Résultats des analyses biologiques suivantes, obtenus dans les 14 jours précédant la première administration du médicament à l’étude.
    7. Une femme en âge de procréer doit avoir un résultat négatif de test sérique de grossesse hautement sensible (gonadotrophine chorionique humaine [hCG, human chorionic gonadotropin]) à la sélection dans les 14 jours précédant l’administration du médicament à l’étude.
    8. L’utilisation d’une contraception par les hommes ou les femmes doit être compatible avec les réglementations locales en vigueur concernant l’utilisation de moyens de contraception chez les sujets participant à une étude clinique.
    9. Pendant l’étude et pendant un minimum d’environ 3 mois après la dernière dose de daratumumab ou 5 mois après la dernière dose d’atézolizumab, en plus du moyen de contraception hautement efficace, un home
    - sexuellement actif dont la partenaire est en âge de procréer doit accepter d’utiliser une méthode barrière de contraception (par exemple, préservatif avec gel/mousse/film/crème/ovule spermicide)
    - sexuellement actif dont la partenaire est enceinte doit utiliser un préservatif
    - doit accepter de ne pas faire de don de sperme.
    10. Volonté et capacité à respecter les interdictions et restrictions spécifiées dans ce protocole
    11. Signature d’un formulaire de consentement éclairé (FCE) indiquant que le patient/la patiente comprend l’objectif de l’étude et les procédures requises pour l’étude, et accepte d’y participer.
    E.4Principal exclusion criteria
    1. Received any of the following prescribed medications or therapies in the past:
    - Anti-CD38 therapy, including daratumumab
    - CD137 agonists, immune checkpoint inhibitors including but not limited to anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapies
    2. Received any of the following prescribed medications or therapies within the specified period:
    - Approved anti-cancer therapy, including chemotherapy, within 3 weeks prior to initiation of study treatment.
    - Other investigational agent or participation in another clinical study with therapeutic intent within 28 days or 5 half-lives of the investigational agent (whichever is longer) to enrollment.
    - Use of systemic corticosteroids ≤2 weeks before Cycle 1 Day 1.
    - Use of systemic corticosteroids ≤10 mg/day prednisone equivalent, or acute use of higher equivalent doses may be allowed with Medical Monitor approval.
    3. Has any of the following conditions:
    - Active or untreated CNS metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during Screening and prior radiographic assessments.
    - Leptomeningeal disease or spinal cord compression not definitively treated with surgery or radiation
    - Uncontrolled tumor-related pain
    4. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently); indwelling catheters are allowed.
    5. Malignancies other than NSCLC within 2 years prior to randomization, with the exception of carcinoma in situ of the cervix or breast, basal or squamous-cell skin cancer, or other malignancy that in the opinion of the investigator and Sponsor’s Medical Monitor is considered cured with a minimal risk of recurrence within 5 years.
    6. History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener’s granulomatosis, Sjögren’s syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.
    7. History of idiopathic pulmonary fibrosis, organizing pneumonia (eg, bronchiolitis obliterans), druginduced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan; history of radiation pneumonitis in the radiation field (fibrosis) is permitted.
    8. Known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <50% of predicted normal. Note that FEV1 testing is required for subjects suspected of having COPD and subjects must be excluded if FEV1 <50% of predicted normal.
    9. Known to be seropositive for human immunodeficiency virus (HIV)
    10. Active hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg] or antibodies to hepatitis B surface and core antigens [anti-HBs and anti-HBc, respectively]) or hepatitis C (anti-HCV antibody positive or HCV-RNA quantitation positive).
    11. Severe infections (including active tuberculosis) within 1 week prior to initiation of study treatment, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia
    12. Screening QTc interval >470 ms.
    13. Clinically significant cardiac disease, including unstable angina, acute myocardial infarction within 6 months from Day 1 of study drug administration, New York Heart Association Class III or IV congestive heart failure, and arrhythmia requiring therapy.
    14. Prior allogeneic bone marrow transplantation or solid organ transplant.
    15. Administration of a live, attenuated vaccine within 4 weeks before first study agent administration.
    16. Women who are pregnant, lactating, or intending to become pregnant during the study or within at least 3 months after last dose of daratumumab or 5 months after the last dose of atezolizumab; men who intend to father a child during the study or within at least 3 months after the last dose of daratumumab or 5 months after the last dose of atezolizumab.
    17. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
    18. Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the daratumumab or atezolizumab formulation.
    19. Any other concurrent medical or psychiatric condition, diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the subject at high risk from treatment complications.
    1.Médicaments ou traitements suivants prescrits précédemment dans les antécédents:Traitement par anti-CD38, y compris daratumumab; Agonistes CD137, inhibiteurs des points de contrôle immunitaires, y compris notamment traitements par anti-CTLA-4, anti-PD-1 et anti-PD-L1 2.Médicaments ou traitements suivants prescrits précédemment pendant la période spécifiée:Traitement anticancéreux approuvé,y compris chimiothérapie,dans les 3 semaines précédant l’instauration du traitement à l’étude;Administration d’un autre agent à l’étude ou participation à une autre étude clinique à visée thérapeutique dans les 28 jours ou les 5 demi-vies de l’agent à l’étude (selon la période la plus longue) avant le recrutement;Corticothérapie systémique ≤ 2 semaines avant le Jour 1 du Cycle 1; Une corticothérapie systémique à une dose ≤ 10 mg/jour d’équivalent de prednisone ou une utilisation aiguë de doses équivalentes plus élevées peuvent être autorisées avec l’approbation du moniteur médical 3.Présence d’une des pathologies suivantes:Métastases actives ou non traitées du SNC,mises en évidence sur la tomodensitométrie (TDM) ou l’imagerie par résonance magnétique (IRM) effectuées pendant la sélection ou sur les examens radiographiques antérieurs;Atteinte leptoméningée ou compression médullaire non traitées définitivement par chirurgie ou radiothérapie;Douleur non contrôlée liée à la tumeur 4.Épanchement pleural non contrôlé, épanchement péricardique ou ascite nécessitant des ponctions répétées (mensuelles ou plus fréquentes);les cathéters à demeure sont autorisés 5.Cancers autres que le CBNPC dans les 2 ans avant la randomisation, sauf carcinome in situ du col de l’utérus ou du sein, épithélioma malpighien spinocellulaire ou carcinome basocellulaire de la peau, ou tout autre cancer considéré comme guéri par l’investigateur et le moniteur médical du promoteur, avec un risque minime de récidive dans les 5 ans 6.Antécédents de maladie auto-immune, y compris notamment :myasthénie grave, myosite, hépatite auto-immune, lupus érythémateux disséminé, polyarthrite rhumatoïde, maladie inflammatoire de l’intestin, thrombose vasculaire associée à un syndrome des anti-phospholipides, granulomatose de Wegener, syndrome de Sjögren, syndrome de Guillain-Barré, sclérose en plaques, vascularite ou glomérulonéphrite 7.Antécédents de fibrose pulmonaire idiopathique, pneumopathie organisée (par exemple, bronchiolite oblitérante), pneumonie médicamenteuse, pneumonie idiopathique ou signes de pneumonie active sur la TDM thoracique de la sélection;les antécédents de pneumonie radique dans le champ d’irradiation (fibrose) sont autorisés 8.Bronchopneumopathie chronique obstructive (BPCO) avec volume expiratoire maximum seconde (VEMS) < 50 % de la valeur normale prédite. Il convient de noter que la mesure du VEMS est exigée chez les patients présentant une suspicion de BPCO,qui devront être exclus si le VEMS est < 50 % de la valeur normale predate 9.Séropositivité connue au virus de l’immunodéficience humaine (VIH) 10.Hépatite B active ou hépatite C active 11.Infections sévères dans la semaine précédant l’instauration du traitement à l’étude, y compris notamment une hospitalisation pour des complications d’infection, bactériémie ou pneumonie severe 12.Intervalle QTc > 470 ms à la selection 13.Cardiopathie cliniquement significative incluant un angor instable, un infarctus aigu du myocarde dans les 6 mois précédant le Jour 1 de l’administration du médicament à l’étude, insuffisance cardiaque congestive de Classe III ou IV NYHA et arythmie nécessitant un traitement 14.Antécédents de greffe de moelle osseuse allogénique ou de greffe d’organe solide 15.Administration d’un vaccin vivant atténué dans les 4 semaines précédant la première administration du médicament à l’étude 16.Pour les femmes: grossesse ou allaitement en cours ou prévision de grossesse pendant l’étude ou dans une période d’au moins 3 mois après la dernière dose de daratumumab ou 5 mois après la dernière dose d’atézolizumab ; pour les hommes: intention d’engendrer un enfant pendant l’étude ou dans une période d’au moins 3 mois après la dernière dose de daratumumab ou 5 mois après la dernière dose d’atézolizumab 17.Antécédents de réactions allergiques, anaphylactiques sévère ou de toute autre réaction d’hypersensibilité à des anticorps chimériques ou humanisés ou des protéines de fusion 18.Hypersensibilité ou allergie connue à des produits biopharmaceutiques produits sur cellules d’ovaire de hamster chinois ou à tout autre composant de la formulation du daratumumab ou de l’atézolizumab 19.Toute autre pathologie médicale ou psychiatrique concomitante, maladie, trouble métabolique, anomalie de l’examen clinique ou des analyses biologiques permettant de suspecter raisonnablement la présence d’une maladie ou d’une pathologie contre-indiquant l’utilisation d’un médicament à l’étude ou pouvant interférer sur l’interprétation des résultats ou augmenter beaucoup le risque de complications liées au traitement
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint is ORR: the proportion of subjects with a partial response (PR) or complete response (CR) as defined by RECIST v1.1 response criteria
    Le critère d’évaluation principal est le TRO : la proportion de patients ayant une réponse partielle (RP) ou complète (RC) selon les définitions des critères de réponse RECIST v1.1
    E.5.1.1Timepoint(s) of evaluation of this end point
    Throughout the whole study.
    Tout au long de l'étude.
    E.5.2Secondary end point(s)
    - Incidence of adverse events
    - DoR: the duration from the date of the initial documentation of a response to the date of the first objectively documented evidence of recurrence or progressive disease or death, whichever status is recorded first.
    - CBR: the proportion of subjects who achieve disease control (CR, PR, or SD with duration of at least 16 weeks).
    - PFS: the duration from the date of randomization to the date of objectively documented progression or death due to any cause, whichever status is recorded first.
    - OS: the duration from the date of randomization to the date of death due to any cause.
    - Serum daratumumab concentration (Cmin, Cmax) and incidence of anti-daratumumab antibodies
    - Serum atezolizumab concentration (Cmin, Cmax) and incidence of anti-atezolizumab antibodies
    - Incidence des événements indésirables
    - DdR : intervalle de temps entre la date de la documentation initiale d’une réponse et la date de la première preuve documentée objectivement de récidive ou de progression de la maladie ou de décès, selon l’événement enregistré en premier.
    - TBC : proportion de patients parvenant à un contrôle de la maladie (RC, RP ou MS avec une durée d’au moins 16 semaines).
    - SSP : intervalle de temps entre la date de la randomisation et la date de la progression de la maladie documentée objectivement ou du décès, de n’importe quelle cause, selon l’événement enregistré en premier.
    - SG : intervalle de temps entre la date de la randomisation et la date du décès, de n’importe quelle cause.
    - Concentration sérique de daratumumab (Cmin, Cmax) et incidence des anticorps anti-daratumumab
    - Concentration sérique d’atézolizumab (Cmin, Cmax) et incidence des anticorps anti-atézolizumab
    E.5.2.1Timepoint(s) of evaluation of this end point
    Throughout the whole study.
    Tout au long de l'étude.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other Yes
    E.7.1.3.1Other trial type description
    Satefy run-in cohort to assess safety/tolerability of atezolizumab administered with daratumumab
    Cohorte préliminaire pour déterminer tolérance et sécurité de l’atézolizumab avec le daratumumab
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned7
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA37
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    France
    Germany
    Hungary
    Spain
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last patient last visit.
    Dernière visite du dernier patient.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months1
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months10
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 38
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 58
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state14
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 69
    F.4.2.2In the whole clinical trial 96
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    No post-trial medication will be provided, the further treatment of patients after end of trial will be carried out according to their physicians' decision.
    Aucun traitement post-essai ne sera fourni, le traitement ultérieur des patients après la fin de l'étude sera effectué selon la décision de leur médecin.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-03-01
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-12-15
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2019-09-26
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA